BiotechTube
Home/Verona Pharma/Mark W. Hahn
MW

Mark W. Hahn

Former CFO

Verona Pharma

Therapeutic Areas

Chronic Obstructive Pulmonary Disease (COPD)AsthmaCystic Fibrosis

Verona Pharma Pipeline

DrugIndicationPhase
Ensifentrine (Nebulized)Maintenance Treatment of COPDApproved
Ensifentrine (pMDI)Maintenance Treatment of COPDPhase 3
EnsifentrineMaintenance Treatment of AsthmaPhase 2

Leadership Team at Verona Pharma

DZ
David Zaccardelli
Former President and CEO
KR
Kathleen Rickard
Former Chief Medical Officer
CD
Clarissa Desjardins
Former Chief Business Officer
View full Verona Pharma profile